Proteomic and phosphoproteomic signatures of disease progression in unmutated IGHV chronic lymphocytic leukemia
Cellular protein patterns distinguish slow-growing from rapidly worsening blood cancer, pointing toward future biomarkers for predicting patient outcomes.
This Mayo Clinic proteomic/phosphoproteomic study of 18 UM-IGHV CLL patients identified molecular signatures distinguishing early-progression from stable disease, with RNA processing and ribosome biogenesis pathways enriched in progressive CLL. These findings are hypothesis-generating biomarker candidates requiring prospective validation in larger cohorts before clinical application.
What the study was
- Study design
- Mass spectrometry-based quantitative proteomics and phosphoproteomics; retrospective discovery cohort
- Population
- UM-IGHV CLL patients; Mayo Clinic Rochester
- Sample size
- 18
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Clinical Proteomics
Why it surfaced
High-depth proteomic characterization of CLL heterogeneity from leading Mayo Clinic group. Score capped due to very small n=18. Hypothesis-generating for biomarker development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.